港股异动 | 康方生物(09926)早盘涨超9% 两款核心产品挂网工作已完成 公司称产品正在快速放量

智通财经
01 Apr

智通财经APP获悉,康方生物(09926)早盘涨超9%,截至发稿,涨8.6%,报82.75港元,成交额6.98亿港元。

消息面上,康方生物在公司业绩会上表示:卡度尼利单抗(商品名:开坦尼)和依沃西单抗(商品名:依达方)年初已完成所有挂网工作(西藏除外),纳入30+省份的双通道目录,实现1000余家医院准入,预计2025年底实现2000+医院覆盖。公司董事会主席夏瑜表示,产品正在快速放量的过程中,现阶段不适合对双抗产品给出业绩指引。

中金发布研报称,2024产品销售额20.02亿元,同比增长25%,产品毛利率为85.56%,销售和营销开支费用率达50.03%,其中开坦尼和依达方销售贡献积极。考虑到公司两款核心产品临床优势明显,以及公司加快销售投入,我们对这两款产品的国内销售持乐观态度。建议关注康方和Summit国内外数据读出。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10